ArticleJournal of tissue engineering
Controlled spatial and temporal release of neurotrophic growth factor from genetically modified tissue engineering living scaffolds.
Article in Journal of tissue engineering. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Development of Acellular Matrix-Based Bioprinted Scaffold for Inferior Alveolar Nerve Regeneration.ACS omega · 2026Article
- Application and Future Perspectives of Extracellular Vesicle-Loaded Scaffold in Spinal Cord Injury.International journal of nanomedicine · 2026Review
- 3D bioprinted multifunctional GelMA/TMP scaffold integrated with neural stem cell-derived extracellular vesicles and neural progenitor cells for spinal cord injury repair.Journal of tissue engineeringArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Peripheral nerve injuries (PNIs) affect thousands of patients yearly, often resulting in loss of function, sensation, and chronic pain. In critical-size defects, advanced surgical repair strategies often fail to restore full function. A key limitation is the lack of sustained, localized delivery of biological cues for axonal regeneration, such as growth factors. Glial-cell line-derived neurotrophic factor (GDNF) is known to promote axonal growth, Schwann cell migration, and neuronal survival, but uncontrolled release may cause axonal entrapment. We previously developed tissue-engineered nerve grafts (TENGs) composed of two neuronal populations connected by stretch-grown axons. In this study, we genetically modified the distal population to express human GDNF under a Tet-on inducible promoter, temporally controlling GDNF release through doxycycline administration. Modified TENGs survived implantation in a 1.5-cm rat sciatic nerve defect, supporting future studies. This approach offers a promising platform for spatially and temporally controlled neurotrophic factor delivery from tissue-engineered living scaffolds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.